Posted by Michael Wonder on 08 Dec 2017
Concentric Analgesics receives FDA fast track designation for CA-008 for post-surgical pain
7 December 2017 - Novel pro-drug with unique mechanism of action takes on the opioid crisis.
Concentric Analgesics announced today that the U.S. FDA has granted fast track designation to CA-008 for the treatment of post-surgical pain. CA-008 is a proprietary water-soluble prodrug that converts into capsaicin, a potent TRPV-1 agonist.
CA-008 is currently being tested in a randomised, double-blind Phase 1b clinical trial, in patients undergoing bunionectomy. The goal of this single, ascending-dose trial is to examine the safety, tolerability and pharmacokinetics of CA-008. Results are expected in the first quarter of 2018.
